Inês Martins, PhD, managing science editor —

Liquidia Technologies, a company developing an inhaled form of treprostinil for pulmonary arterial hypertension (PAH), has established an agreement to acquire the rare disease company and marketer of generic treprostinil injections, RareGen, strengthening the company’s efforts in the PAH field. Under the agreement, the two companies will…

Gene expression patterns in the lungs can help distinguish pulmonary arterial hypertension (PAH) from pulmonary veno-occlusive disease (PVOD) — a subtype in which the narrowing of veins, instead of arteries, causes pulmonary hypertension — with high accuracy, a study reported. Findings also showed that lung diseases share similar alterations…

Aerami Therapeutics has entered an agreement with Vectura Group to develop and commercialize an inhaled form of imatinib — an approved cancer therapy — for the treatment of people with pulmonary arterial hypertension (PAH). Under the agreement, Aerami will be solely responsible for developing this new…

A composite assessment of voice features may be able to monitor changes in the pulmonary arteries of people with pulmonary hypertension (PH) who are at risk of heart failure, helping identify those more likely to experience poor outcomes, a study found. While these patients usually require invasive tests to…

Chronic inhalation of nicotine, the addictive component of all tobacco products, is enough to trigger changes in pulmonary arteries and in the heart’s right chamber that can cause pulmonary hypertension (PH), a recent study in mice found. The study, “Effects of Chronic Nicotine Inhalation on…

Tricumed‘s LENUS Pro pump, an implantable device approved in Europe for the long-term intravenous administration of Remodulin (treprostinil) to treat pulmonary arterial hypertension (PAH), does not maintain a steady flow rate over time, a study of refill data reports. The analysis found flow rates lower than those specified by…

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Acceleron Pharma‘s investigational molecule sotatercept for the treatment of pulmonary arterial hypertension (PAH). Breakthrough designation is given to medications that have the potential to provide…

Despite previous evidence to the contrary, a single-center study suggests that sex hormones do not influence the development or progression of pulmonary arterial hypertension (PAH), nor do they explain the higher prevalence of PAH in women. Exposure to sex hormones, either due to external sources like oral contraceptives…

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are successfully treated with pulmonary endarterectomy (PEA) may be at increased risk of having low levels of oxygen in the blood due to severe pulmonary arteriopathy, a condition characterized by pulmonary artery remodeling, according to a study from Chiba University in Japan. The…

People infected with HIV are known to have a greater incidence of pulmonary hypertension and to be an almost 2,500-fold higher risk of developing PH than others, and a new study looked at HIV-infection and PH rates in Africa, a continent with the highest prevalence of HIV infections worldwide. The study, “Prevalence…

The vascular constrictor coupling factor 6 (CF6) is involved in the development of pulmonary arterial hypertension by creating an imbalance in the inner lining of lung blood vessels, part of larger process known as endothelial dysfunction, according to a recent study by Chinese researchers. The study, “Lung-specific RNA interference of…

Reata Pharmaceuticals recently provided an update on its clinical candidates and their developmental, including its Phase 2 proof-of-concept studies into bardoxolone methyl as a potential treatment for various types of pulmonary hypertension and omaveloxolone for neuromuscular diseases. Bardoxolone methyl is being developed for patients with pulmonary arterial hypertension (PAH), or high…